Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated October 13, 2022, serves as a transaction notification for the month of October 2022. The document details share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions.
| Transaction Date | Instrument | Transaction Price | Total Volume (Shares) | Exchange |
|---|---|---|---|---|
| 2022-10-11 | Ordinary Shares (31 1/2 pence each) | £13.5718 | 19,849.573 | London Stock Exchange (XLON) |
Note: Total volume is the aggregate of 11 individual transactions listed in the filing.
Material Changes
The filing does not contain comparative financial data or material changes to the company's business operations versus prior periods. The only reported activity is the acquisition of shares by executives and their associates.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions are routine acquisitions following the reinvestment of dividends paid to shareholders on October 11, 2022.
Investor Verification Checklist
- Verify the total number of shares acquired by PDMRs and PCAs (19,849.573 shares) against the company's insider trading registry.
- Confirm the transaction price of £13.5718 aligns with the market price of GSK ordinary shares on October 11, 2022.
- Review the dividend reinvestment plan terms to ensure the acquisitions were executed automatically as described.
- Check subsequent filings for any changes in beneficial ownership percentages resulting from these transactions.